Výsledky vyhledávání - "Joanne, Palmisano"

The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE Trial Sub-study

Autor: Adrian S. Dobs, Joanne Palmisano, Michael Miller, Wendy P. Battisti, Zhong Yuan

Publikováno v: Current Medical Research and Opinion. 22:343-350

To determine if simvastatin effectively decreases the elevated levels of triglyceride (TG), TG-rich lipoproteins, and small, dense LDL particles, which are characteristic of diabetic dyslipidemia.We conducted a prespecified analysis from a double-bli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f8ebe6d067aee072b0cd2dcdbc53db5
https://doi.org/10.1185/030079906x80521

Zobrazit plný text záznamu

Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: Subanalyses of data from a randomized, double-blind, placebo-controlled trial

Autor: Joanne Palmisano, Margo A. Denke, Wendy P. Battisti, William E. Brady, Thomas A. Pearson, Patrick E. McBride

Publikováno v: The American Journal of Geriatric Pharmacotherapy. 3:218-228

Background: The Ezetimibe Add-on to Statin for Effectiveness (EASE) trial examined the effectiveness and safetyprofile of ezetimibe (EZE) added to ongoing statin therapy in 3030 patients with low-density lipoprotein cholesterol (LDL-C) levels exceedi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::22c379a167fdfc10bbf7c9260b0163c2
https://doi.org/10.1016/j.amjopharm.2005.12.009

Zobrazit plný text záznamu

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)

Autor: Joanne Palmisano, Zhong Yuan, Gloria Lena Vega, William E. Brady, Wendy P. Battisti, Scott M. Grundy

Publikováno v: The American Journal of Cardiology. 95:462-468

Patients with combined hyperlipidemia (elevated triglyceride [TG] levels, elevated low-density lipoprotein [LDL] cholesterol, and multiple lipoprotein abnormalities) are at increased risk for coronary heart disease. We conducted a multicenter (in the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ae69393268bdc1a5840d5850cf14bf5
https://doi.org/10.1016/j.amjcard.2004.10.012

Zobrazit plný text záznamu

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia

Autor: Christie M. Ballantyne, Thomas R. King, Joanne Palmisano, Michael A. Blazing, William E. Brady

Publikováno v: The American Journal of Cardiology. 93:1487-1494

This study compared the efficacy and safety of co-administered ezetimibe + simvastatin with atorvastatin monotherapy in adults with hypercholesterolemia. Seven hundred eighty-eight patients were randomized 1:1:1 to 3 treatment groups; each group was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52311e6a9817c8939c20ece3410f60f5
https://doi.org/10.1016/j.amjcard.2004.02.060

Zobrazit plný text záznamu

A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d

Autor: Helene M. Wilson, Mary R. Dicklin, Joanne Palmisano, Michael H. Davidson, Charles Liss

Publikováno v: Clinical Therapeutics. 25:2738-2753

Background: The available statin drugs have similar pharmacodynamic properties but are not equal in low-density lipoprotein cholesterol (LDL-C)—lowering efficacy. Objective: The aim of this study was to compare the effects of lovastatin and fluvast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a64e4ba11501bf7223f810080057a5
https://doi.org/10.1016/s0149-2918(03)80330-2

Zobrazit plný text záznamu

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study

Autor: Joanne Palmisano, Mary E. Smith, James A. Simon, Lixia Wang, Richard A. Petruschke, E. Michael Lewiecki

Publikováno v: Clinical Therapeutics. 24:1871-1886

Alendronate, an oral bisphosphonate, is available for the treatment of osteoporosis in a 70-mg once-weekly and a 10-mg once-daily formulation.This study aimed to determine patient preference for once-weekly versus once-daily dosing with alendronate,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fb83364e2b826553a6191d6bbc4a4e3
https://doi.org/10.1016/s0149-2918(02)80085-6

Zobrazit plný text záznamu

Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms

Autor: John Yates, Paul D. Miller, Barbara Mako, Mary E. Smith, Angelo A. Licata, Joanne Palmisano, Lixia Wang, Mary E. Melton, Grattan Woodson, Mark P. Ettinger

Publikováno v: Clinical Therapeutics. 22:1433-1442

Background: There have been reports from physicians in clinical practice that up to 30% of patients taking bisphosphonate therapy develop upper gastrointestinal (UGI) symptoms, many or most of which they assume to be related to the drug. However, in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f485ca130f4316214321e9e24875a205
https://doi.org/10.1016/s0149-2918(00)83042-8

Zobrazit plný text záznamu

Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial

Autor: Patrick E. McBride, Thomas A. Pearson, Joanne Palmisano, Margo A. Denke, William E. Brady, Russell A. Gazzara, Wendy P. Battisti

Publikováno v: Mayo Clinic proceedings. 81(9)

To examine whether the improvements in lipid profiles and low-density lipoprotein cholesterol (LDL-C) goal attainment found in the Ezetimibe Add-On to Statin for Effectiveness trial occurred equally in the black, Hispanic, and white patient populatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a5ab5bb2446b67122ed54ef24153222
https://pubmed.ncbi.nlm.nih.gov/16970214

Zobrazit plný text záznamu

LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD

Autor: James, McKenney, Christie M, Ballantyne, Theodore A, Feldman, William E, Brady, Arvind, Shah, Michael J, Davies, Joanne, Palmisano, Yale B, Mitchel

Publikováno v: MedGenMed : Medscape general medicine. 7(3)

To compare the proportion of patients at high risk for coronary heart disease (CHD) achieving the recommended low-density lipoprotein cholesterol (LDL-C) treatment goal of100 mg/dL and the optional LDL-C target of70 mg/dL with coadministration of eze

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ef53e3c2849a11d2bdad0bbb3872d949
https://pubmed.ncbi.nlm.nih.gov/16369229

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání